27.5 C
Vientiane
Saturday, August 23, 2025
spot_img
Home Blog Page 918

DPC Dash – Domino’s Pizza China Shows Growth Momentum, While Building Resilient Community in the First Quarter of 2025

HONG KONG, April 7, 2025 /PRNewswire/ — DPC Dash – Domino’s Pizza China (“DPC Dash” or the “Company”) (1405.HK), Domino’s Pizza’s exclusive master franchisee in the China Mainland, the Hong Kong Special Administrative Region of China, and the Macau Special Administrative Region of China, continued to demonstrate growth momentum in the first quarter of 2025, while building a resilient community through its proven 4D strategy of Development, Delicious Pizza at Value, Delivery, and Digital, further consolidating its industry-leading position.

According to Frost & Sullivan, DPC Dash ranked second in pizza sales nationwide in 2024. The Chinese mainland market ranks as the third-largest Domino’s Pizza international market by store count as of December 31, 2024. In the first quarter of 2025, DPC Dash continued to strengthen its market share, demonstrating significant benefits from its penetration strategy. As reported in the First Quarter 2025 Investor Fact Sheet (“investor fact sheet”), DPC Dash operated 1,105 stores in 45 cities across mainland China as of March 31, 2025.

DPC Dash continues to adopt the “go-deeper, go-broader” store network strategy, maintaining a healthy and rapid growth of its store network. At the start of 2025, DPC Dash entered six new cities, accelerating its penetration into lower-tier cities. Along with the expansion in new store numbers, DPC Dash has further established a global sales benchmark. The same-store sales growth (SSSG) in first quarter of 2025 remained positive and marked the 31st consecutive quarter of positive SSSG since the current management took over in the third quarter of 2017. As of the first quarter of 2025, DPC Dash holds all 40 top positions in Domino’s global system for first 30-day sales, proving its brand appeal and operational capability in mainland Chinese cities. On March 3, 2025, DPC Dash received the Gold Franny Award from Domino’s Pizza, Inc. for the seventh consecutive year. This award recognizes U.S. and international franchisees within the Domino’s global system for outstanding operating results, store development, and growth.

As of March 31, 2025, the number of net new stores opened, stores currently under construction, and stores that have signed for DPC Dash has reached nearly 61% of the total targeted store opening plan for the full year, with 97 new stores opened in the first quarter, steadily advancing its high-quality expansion plan.

With this growth, DPC Dash is building a resilient community, with 27.2 million loyalty program members as of March 31, 2025. Over the past 12 months, 12.6 million new customers placed their first orders with Domino’s Pizza China. DPC Dash continues to leverage its digital initiatives to drive customer engagement and attract a large number of new customers through multiple online channels, while also enhancing its capability to offer personalized rewards, effectively improving new customer conversion and existing customer retention.

In the first quarter of 2025, DPC Dash continued to activate consumer demand through product and marketing innovations. The company launched several new products and limited-time promotions, including Singapore Style Sausage & Chicken Pizza, American Style Beef Bacon Pineapple Pizza, Avocado Double Decker, and snacks, alongside a limited-time free crust upgrade promotion with terms and conditions apply. During the Lunar New Year, the company partnered with the popular NetEase-developed video game Egg Party for a co-branded marketing campaign and introduced its signature “Mega Week (BOGO)” promotion at the end of the quarter, further boosting consumer interest.

Meanwhile, DPC Dash actively builds an ideal workplace for employees, leading transformation, inspiring potential, and accelerating overall achievement. In the first quarter of 2025, DPC Dash was recognized as a 2024 Best Employer by Mercer for its exceptional performance in employee engagement, agility, engaging leadership and talent focus, marking the third consecutive year that the Company has received this prestigious award.

Looking ahead, DPC Dash will remain committed to offering delicious pizza at value, enhancing dining and consumption experiences, and creating sustainable long-term value for consumers, investors, employees, and other stakeholders.

About DPC Dash Ltd

DPC Dash is Domino’s Pizza’s exclusive master franchisee in the Chinese mainland, the Hong Kong Special Administrative Region of China and the Macau Special Administrative Region of China. Domino’s Pizza, Inc., DPC Dash’s global franchisor, is one of the most widely-recognized global consumer brands and the world’s largest pizza company. Led by a seasoned and visionary management team, DPC Dash is a market leader that differentiates from competitors with, among others, a continually innovated and localized pizza-focused menu, unique expertise and leadership in delivery, technology focus and scalable and replicable store economic model. DPC Dash operates 1,105 stores in 45 cities in the Chinese mainland as of March 31, 2025.

For more information, please visit www.dpcdash.com 

For official company announcements, please visit www.hkexnews.hk 

Contacts

DPC Dash Ltd Investor Relations:
DPC Dash Ltd
IR@dominos.com.cn 

ICR, LLC
dpcdashIR@icrinc.com 

DPC Dash Ltd Media Relations:
ICR, LLC
dpcdashPR@icrinc.com 

Huatai Securities Shares FinTech Practices with Hong Kong SFC


HONG KONG SAR – Media OutReach Newswire – 7 April 2025 – ​Huatai Securities recently hosted a FinTech knowledge-sharing session with the Hong Kong Securities and Futures Commission (SFC). The event aimed to share forward-looking perspectives on financial technology and contribute to shaping the future of financial services in an increasingly AI-driven landscape.

The session covered financial-specific large language models, intelligent credit research, and innovations in the fixed income, currencies, and commodities (FICC) trading platform. Drawing on its own expertise, the company shared its latest progress in infrastructure and platform development, along with its efforts to integrate artificial intelligence into financial applications, on which the company has placed strong emphasis in recent years.

During the session, the company’s technical experts reviewed AI large language model developments globally and in China. The company presented its system of large model platform that integrates computing power, operational management, and application development. The experts demonstrated how LLM is already improving workflows across research, advisory, and investment banking services, both internally and with partners. The company is also exploring ways to enhance client services using intelligent tools across various business areas.

The session included real-world case studies across various asset classes, showing how its Credit Analysis Management System (CAMS) enables quantitative credit assessment, real-time risk tracking, credit bond pricing and regulatory empowerment. Huatai Securities started developing CAMS in 2017, combining extensive market data with quantitative models and AI. Today, as the backbone of Huatai’s credit research ecosystem, it is widely used in credit risk management, trading, and investment research, and has strong potential for application in investment banking and asset management.

In response to evolving FICC market dynamics, the company has upgraded its Global FICC Electronic Trading Platform (HEADS) to manage strategy development, trade execution, and risk assessment across all asset classes in both domestic and international markets, including exchange-traded and over-the-counter products, connecting research to trading in a seamless process. Looking ahead, HEADS will strengthen its capabilities in overseas FICC trading, investment, and risk management, leveraging AI to create new products and build an integrated client service system.

This year marks Huatai Securities’ 10th anniversary of listing on the Hong Kong Stock Exchange, a milestone that accelerated the company’s international expansion. The company now runs a connected financial network across Mainland China, Hong Kong, the US, the UK, Singapore, and other regions, with technology supporting both local and international business. As it grows globally, Huatai is building stronger technology capabilities to empower business growth, using its platforms to connect assets, clients, and products while expanding its global presence.

Hashtag: #huataisecurities

The issuer is solely responsible for the content of this announcement.

About Huatai Securities

Incorporated in April 1991, Huatai Securities is a leading technology-driven securities group in China, with a highly collaborative business model, a cutting-edge digital platform and an extensive and engaging customer base. It provides comprehensive financial services to individual and institutional clients, including wealth management, investment banking, sales and trading, investment management, among others, with a substantial international presence.

Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., April 7, 2025 /PRNewswire/ — Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy for the treatment of adults with schizoaffective disorder.

ERZOFRI, administered once a month, delivers the active ingredient, paliperidone, through a long-acting, extended-release delivery system. It simplifies treatment by enabling single-dose initiation due to its unique 351 mg initiation dose. The currently prescribed monthly paliperidone palmitate long-acting injectable (LAI) requires two initiation doses, on Day 1 and Day 8.

ERZOFRI may cause serious side effects, including:
Increased risk of death in elderly people with dementia-related psychosis. ERZOFRI increases the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ERZOFRI is not for the treatment of people with dementia-related psychosis. The most common side effects of ERZOFRI include injection site reactions, sleepiness or drowsiness, dizziness, feeling restless or like you need to move, and abnormal muscle movements including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes.

Both schizophrenia and schizoaffective disorder are severe, chronic psychiatric disorders characterized by recurrent relapses[1]. Non-adherence to medication is a major challenge in patients with such conditions. Failure of follow-up care after discharge significantly increases patients’ non-adherence to prescribed medications, relapse and rehospitalization[2]. LAI antipsychotics, with a reduced dosage frequency compared to oral antipsychotics, effectively improve medication adherence and reduce the risk of healthcare providers not knowing if their patients fail to follow the prescribed dosage regimen[3].

ERZOFRI’s approval by the FDA is based on the results of an open-label, randomized, multiple-dose, parallel-group study evaluating its pharmacokinetic (PK) profile and relative bioavailability at steady state versus an established paliperidone palmitate LAI drug for reference. The study demonstrated the bioequivalence of ERZOFRI to the listed drug at steady state (treatment day 8) without the need for a second initiation injection.

Comparable total drug exposure and a safety profile consistent with the listed drug were established. In addition to the unique 351 mg/2.25mL initiation dose, ERZOFRI is available in single-use kits in the following strengths: 39 mg/0.25mL, 78 mg/0.5 mL, 117 mg/0.75 mL, 156 mg/mL, and 234 mg/1.5 mL.

“This newly approved long-acting injectable antipsychotic for the management of schizophrenia can help address treatment initiation complexities and provides an exciting alternative to help patients reach their treatment goals.” said Christoph U Correll, MD, Professor of Psychiatry, Zucker School of Medicine at Hofstra/Northwell, New York, USA.

Rongbing Yang, President of Luye Pharma Group, added: “Medication adherence and discontinuation present a major challenge in the treatment of schizophrenia and schizoaffective disorder. Using LAIs is effective in increasing medication adherence. ERZOFRI, with its simplified dosage regimen eliminating the need for a second dose when initiating treatment is expected to increase treatment adherence in the initial stage. Its commercial launch in the U.S. marks a major milestone in our commitment to addressing the unmet medical needs of patients in the U.S. The central nervous system is a key therapeutic area of focus for Luye Pharma, and we are committed to providing innovative therapies to combat mental disorders and expand treatment options.”

 

ERZOFRI® (paliperidone palmitate) extended-release injectable suspension
INDICATIONS

What is ERZOFRI® (paliperidone palmitate)?

ERZOFRI is a prescription medicine given by injection by a healthcare provider and used to treat:

  • schizophrenia in adults
  • schizoaffective disorder in adults either alone or with other medicines such as mood stabilizers or antidepressants

It is not known if ERZOFRI is safe and effective in children.

 

IMPORTANT SAFETY INFORMATION FOR ERZOFRI (paliperidone palmitate)
ERZOFRI may cause serious side effects, including:
Increased risk of death in elderly people with dementia-related psychosis. ERZOFRI increases the risk of death in elderly people who have lost touch with reality (psychosis) due to confusion and memory loss (dementia). ERZOFRI is not for the treatment of people with dementia-related psychosis.

Do not receive ERZOFRI if you are allergic to paliperidone, risperidone, or any of the ingredients in ERZOFRI.

What are the possible serious side effects of ERZOFRI?

Cardiovascular problems (including stroke) in elderly people with dementia-related psychosis that can lead to death.

Neuroleptic Malignant Syndrome (NMS) a serious condition that can lead to death. Call your healthcare provider right away or go to your nearest emergency room right away if you get any of the following signs or symptoms:

  • high fever
  • stiff muscles
  • confusion
  • sweating
  • changes in your breathing, pulse, heart rate, or blood pressure

Problems with your heartbeat. These heart problems can cause death. Call your healthcare provider right away if you get any of these symptoms:

  • passing out or feeling like you will pass out
  • dizziness
  • feeling as if your heart is pounding or missing beats

Uncontrolled body movements (tardive dyskinesia). ERZOFRI may cause movements that you cannot control in your face, tongue, or other body parts. Tardive dyskinesia may not go away, even if you stop taking ERZOFRI. Tardive dyskinesia may also start after you stop taking ERZOFRI.

Problems with your metabolism such as:

  • High blood sugar (hyperglycemia) and diabetes. Increases in blood sugar can happen in some people who are treated with ERZOFRI. Extremely high blood sugar can lead to coma or death. If you have diabetes or risk factors for diabetes such as being overweight, or a family history of diabetes, your healthcare provider should check your blood sugar before you start treatment and during your treatment with ERZOFRI.

    Call your healthcare provider if you get any of these symptoms of high blood sugar during treatment with ERZOFRI:
    • feel very thirsty
    • feel very hungry
    • feel sick to your stomach
    • need to urinate more than usual
    • feel weak or tired
    • feel confused, or your breath smells fruity
  • Increased fat levels (cholesterol and triglycerides in your blood). Your healthcare provider may check your cholesterol and triglyceride levels during treatment with ERZOFRI.
  • Weight gain. You and your healthcare provider should check your weight regularly during treatment with ERZOFRI.

Decreased blood pressure (orthostatic hypotension) and fainting. You may feel lightheaded or faint when you rise too quickly from a sitting or lying position.

Falls. ERZOFRI may make you sleepy or dizzy, may cause a decrease in your blood pressure when changing position (orthostatic hypotension), and can slow your thinking and motor skills which may lead to falls that can cause fractures or other injuries.

Low white blood cell counts. Your healthcare provider may do blood tests during treatment with ERZOFRI.

Increased prolactin levels in your blood (hyperprolactinemia). ERZOFRI may cause a rise in the blood levels of a hormone called prolactin that may cause side effects including missed menstrual periods, a reversible reduction in fertility in females who are able to become pregnant, leakage of milk from the breasts, development of breasts in men, or problems with erection.

Sleepiness, drowsiness feeling tired, difficulty thinking and doing normal activities.

Seizures (convulsions).

Difficulty swallowing that can cause food or liquid to get into your lungs.

Prolonged or painful erection lasting more than 4 hours (priapism). Call your healthcare provider or go to your nearest emergency room right away if you have an erection that lasts more than 4 hours.

Problems with control of your body temperature so that you feel too warm.

 

Before taking ERZOFRI, tell your healthcare provider about all of your medical conditions including if you:

  • have never taken paliperidone or risperidone before
  • have had neuroleptic malignant syndrome (NMS)
  • have or had heart problems, including heart attack, heart failure, abnormal heart rhythm, or long QT syndrome
  • have or had low levels of potassium or magnesium in your blood
  • have or had uncontrolled movements of your tongue, face, mouth or jaw (tardive dyskinesia)
  • have or had kidney or liver problems
  • have or had high blood sugar, diabetes or have a family history of diabetes
  • have or had high levels of total cholesterol, LDL cholesterol, or triglycerides, or low levels of HDL cholesterol
  • have Parkinson’s disease or a type of dementia called Lewy Body Dementia
  • have or had problems with dizziness or fainting or are being treated for high blood pressure
  • have or had a low white blood cell count
  • have or had seizures or epilepsy
  • are pregnant or plan to become pregnant. It is not known if ERZOFRI will harm your unborn baby.
    • If you become pregnant during treatment with ERZOFRI, talk to your healthcare provider about registering with the National Pregnancy Registry for Atypical Antipsychotics. You can register by calling 1-866-961-2388 or visit http://womensmentalhealth.org/clinical-and-research-programs/pregnancyregistry/.
    • Babies born to women who are treated with ERZOFRI during their third trimester of pregnancy may experience symptoms such as tremors, irritability, excessive sleepiness, eye twitching, muscle spasms, decreased appetite, difficulty breathing, or abnormal movement of arms and legs. Let your healthcare provider know if these symptoms occur.
  • are breastfeeding or plan to breastfeed. ERZOFRI can pass into your breastmilk.
    • Talk to your healthcare provider about the best way to feed your baby if you receive ERZOFRI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ERZOFRI and certain other medicines may affect each other causing possible serious side effects or affect the way each other works. Know the medicines you take. Keep a list of them to show to your healthcare provider or pharmacist when you get a new medicine.

 

The most common side effects of ERZOFRI include:

  • injection site reactions
  • sleepiness or drowsiness
  • dizziness
  • feeling restless or like you need to move
  • abnormal muscle movements including tremor (shaking), shuffling, uncontrolled involuntary movements, and abnormal movements of your eyes

Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects of ERZOFRI. Call your doctor for medical advice about side effects. You may report side effects to FDA at www.fda.gov/medwatch or call 1-800- FDA-1088.

 

About Luye Pharma Group

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of over 20 drug candidates in China and more than 10 drug candidates in other international markets. Luye Pharma maintains high-level international standards in novel drug delivery technologies including microspheres, liposomes, and transdermal drug delivery systems. The company has achieved multiple innovations in new chemical entities and antibodies, and is also actively making strategic developments in the fields of cell therapies and gene therapies.

Luye Pharma is developing a global supply chain of 8 manufacturing sites built up around the world, with GMP quality management and control systems established in line with international standards. With more than 30 products covering the central nervous system, oncology, cardiovascular, metabolism and other therapeutic areas, business is conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets — China, the U.S., Europe and Japan, as well as in fast-growing emerging markets.

[1]. Anne Rivelli, Veronica Fitzpatrick, Michael Nelson, et al. Real-world predictors of relapse in patients with schizophrenia and schizoaffective disorder in a large health system. Schizophrenia (Heidelb) (2024). DOI: 10.1038/s41537-024-00448-2.

[2]. Lee SY, et al. Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based Study. Psychiatry Investig. 2015;12(4):425-33. DOI: 10.4306/pi.2015.12.4.425

[3]. Carmela Benson, et al. Treatment patterns and hospitalizations following rejection, reversal, or payment of the initial once-monthly paliperidone palmitate long-acting injectable antipsychotic claim among patients with schizophrenia or schizoaffective disorder. J Manag Care Spec Pharm. 2024 Jun 3:1-13. DOI: 10.18553/jmcp.2024.23252.

US-ERZ-PM-250300020-v1.0-03/2025

 

 

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr. Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.  

Dr. Schaffer has been CTO at ARTMS Inc. (ARTMS) (acquired by Telix in 2024) for the past seven years, as well as Director, Life Science at TRIUMF, Canada’s particle accelerator research centre, since 2012. Based in Vancouver, Canada, Dr. Schaffer is widely recognized for his role in the buildout and transformation of the TRIUMF Life Sciences program, which included design and construction of a major multi-cyclotron radiochemistry facility and the development of the ARTMS QUANTM Irradiation System® (QIS®) for large-scale isotope production, which was commercialized and later acquired by Telix.

As Telix CTO, Dr. Schaffer will be responsible for harnessing the power of technology to advance Telix’s capabilities in radiopharmaceutical research, development, and clinical applications. Dr. Schaffer will cover areas including chemistry, physics, artificial intelligence (AI), dosimetry, and data analytics, complementing the work of Telix’s Chief Scientist, Dr. Michael Wheatcroft, and his team in driving cutting-edge research and development (R&D).

Dr. Schaffer said, “I’m excited to be taking on this role at such a pivotal time for Telix, as the Company advances rapidly toward its mission of transforming patient care. Telix has a bold commitment to innovation, and I’m thrilled to collaborate with this talented team to help drive R&D for the technologies behind the next generation of radiotherapeutics.”

Dr. Christian Behrenbruch, Telix Managing Director and Group Chief Executive Office, said, “Paul has an impressive track record of driving innovation in life sciences technology, including his groundbreaking work in large-scale isotope production. I have first-hand experience of Paul’s impressive intellect, ideas and passion through his work at TRIUMF and with ARTMS, so it is a great pleasure to have him join the broader Telix team as we continue to lead radiopharmaceutical innovation.”

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedInX and Facebook.

Telix Investor Relations
Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

QC Ware Announces 4th Q2B Tokyo Conference Focused on the Roadmap to Quantum Value in Asia and Beyond, Quemix to Co-host and Sponsor

QC Ware hosts the 4th Q2B conference in Tokyo to connect the Asian and global quantum technology landscape and bring together quantum industry experts across computing, AI, telecommunications, sensing, finance, automotive, chemicals, and more.

PALO ALTO, Calif., April 7, 2025 /PRNewswire/ — QC Ware, a leading provider of industry-disrupting quantum technology, quantum-inspired machine learning, and quantum chemistry simulation solutions, today announced the 2025 Q2B Tokyo Conference (Q2B25) taking place May 15-16, 2025.

As the Q2B25 Tokyo Co-host and Platinum Sponsor, Quemix will contribute to discussions and demonstrations aimed at accelerating the adoption of quantum technologies in various industries, spanning pharmaceutical, biotech, finance, automotive, logistics, and artificial intelligence. “Quemix is honored to be a co-host of Q2B Tokyo 2025. We’re incredibly excited to see the robust ecosystem that will shape the future of quantum technology being built here,” said Quemix CEO and President, Yu-ichiro Matsushita.

The conference, being held at the Grand Hyatt Tokyo, will dive deep into all major quantum technologies and themes: computing, sensing, communications, security, error correction, quantum AI, HPC integration, and more. Attendees can expect to see featured keynotes, industry case studies, and discussions led by experts at the forefront of quantum R&D from some of the world’s leading businesses and institutions across government, academia, and industry.

“It’s a pleasure to be back in Tokyo for another Q2B event. Japan’s quantum community continues to impress with its innovation, collaboration, and global leadership.  The strong engagement of Japanese industrial end users, who are actively exploring and adopting quantum technologies, drive real-world impact across various sectors.  We’re excited to engage with this vibrant landscape shaping the future of quantum,”  said QC Ware CEO, Matt Johnson. “The quantum ecosystems of Japan and Asia are incredibly dynamic and exciting, and the work undertaken to directly and indirectly create that environment cannot be overstated.”

Through keynotes, business seminars, breakout sessions, technical workshops, and panel discussions, attendees at Q2B Tokyo will learn about the latest hardware and software breakthroughs as well as applications in optimization, chemistry simulations, pharmaceutical and materials discovery, error correction, and quantum AI. Additionally, the conference features several panels and sessions from field practitioners, end users, and experts across industries. Notable speakers include:

  • Jingo Kikukawa – Director-General, Innovation and Environment Policy Bureau, Ministry of Economy Trade and Industry (METI)
  • Taro Shimada – Chair of the Board, Quantum Strategic Industry Alliance for Revolution (Q-STAR) and CEO, Toshiba
  • Prof Seigo Tarucha – Research Group Director, RIKEN
  • Yu-ichiro Matsushita – CEO, Quemix
  • Shuya Kekke – CEO and Representative Director, Quantinuum K.K.
  • Dr. Michael J. Biercuk – CEO and Founder, Q-CTRL
  • Seiji Kihara – Member of the House of Representatives /Chairperson, Election Strategy Committee, Liberal Democratic Party
  • D. Eng. Seiji Yunoki – Team Leader, RIKEN
  • Yoshihiro Maeda – Chief Growth Officer, Deloitte Tohmatsu
  • Doug Finke – Chief Content Officer, GQI

Q2B is dedicated to promoting and growing the quantum technologies landscape with applied implementation examples via the case studies track. This track is dedicated to real-world applications of quantum technologies and provides case studies from industrial end users who have already started their quantum journey. Leaders charting the future of quantum technology adoption will deliver sessions on recent advancements in the field, including:

  • Qi Gao – Senior Chief Scientist, Mitsubishi Chemical Corporation
  • Carmen Palacios – Founder and CEO, Nu Quantum
  • Oded Melamed – CEO and Co-founder, Quantum Source
  • Dr. Netanel Lindner – Professor of Physics, Co-founder and CTO, Qedma
  • Constanza Vidal Bustamente – Fellow, Technology and National Security, Center for a New American Security
  • Shaukat Ali – Chief Research Scientist, Simula Research Laboratory
  • Masahiro Horibe – Deputy Director, AIST/G-QuAT
  • Marcus Doherty – Co-founder and CTO, Quantum Brilliance
  • Dr. Shintaro Sato – Head of Quantum Lab, Fujitsu Research
  • Masaru Watabiki – Senior Expert, Toshiba Digital Solutions Corporation
  • Vladimir Tsitrin – Quantum Security Research Lead, Fidelity Center for Applied Technology
  • Shihan Sajeed – Program Director, Wellcome Leap
  • Shunsuke Okada – Executive Director, Q-STAR

Attendees will also have the opportunity to explore the exhibit floor with vendors showcasing their latest advancements in quantum technologies, featuring: Quemix, Keysight, Quantinuum, QuEra Computing, Qedma, Quantum Machines, IonQ, Toshiba, Fujitsu, RIKEN, Classiq, Oxford Quantum Circuits, IQM, Toyota Tsusho, Lquom, NF Corporation, Alpine Quantum Technologies, Q-STAR, and more.

Find the agenda, featured speakers and register to attend Q2B25 Tokyo here.

About QC Ware
QC Ware is a quantum and classical computing SaaS company focused on delivering enterprise value through cutting-edge computational technology. The company develops enterprise-grade applications that run on state-of-the-art classical computing hardware and algorithms targeting near-term quantum hardware. Its flagship product, Promethium, is an advanced molecular discovery platform that leverages quantum chemistry to accelerate research across pharmaceutical, materials science, and chemical industries. With specialization in machine learning and chemistry simulation applications, the team bridges the gap between theoretical quantum computing and practical business solutions. Composed of some of the industry’s foremost experts, QC Ware is headquartered in Palo Alto, California, with a European subsidiary in Paris. The company also organizes Q2B, a global series of conferences for industry, practitioner, and academic quantum computing communities. Learn more at www.qcware.com.

CONTACT: Jean-Baptiste Faverjon, +33777847234, jb.faverjon@qcware.com 

Trip.com Kicks Off Mega Sale on Flights & Hotels to Celebrate Easter

SYDNEY, April 7, 2025 /PRNewswire/ — Trip.com is thrilled to launch its Easter Mega Sale, offering an array of exciting travel deals and exclusive promotions. Get ready to pack your bags to your dream destination. From 1 April to 27 April, Trip.com is offering fantastic discounts with promo codes for up to 50% off flights and accommodation, making it easier than ever to save big and explore the world.


Unlock Unbeatable Airfare Deals

Whether you’re looking to hop on a staycation or jet-set internationally, Trip.com has you covered.  Customers can save more than AU$1,000 this Easter Sale with airline promo codes from China Eastern Airlines, Scoot, Air India, Sichuan Airlines, and more, available starting 9 am AEST on 8 April. Plus, customers still have the chance to get flight promo codes worth up to 50% off. Offer starts 12 pm AEST on 8 April until 11:59 pm AEST on 8 April, on a first-come, first-served basis, while stocks last.

Customers can also grab unbeatable deals on international and domestic flights during Trip.com’s #TripTuesday Flight Flash Sale. One-way flights between Sydney, Melbourne, Brisbane, Adelaide and the Gold Coast start from just AU$29, including taxes and fees.  Only one order per customer, subject to T&Cs.

Alternatively, travellers looking to explore Bali’s vibrant streets and pristine beaches can fly from Perth to Bali one way for an incredible price of AU$109.

Stay & Play with a Fantastic Hotel Giveaway 

Trip.com customers can win a 3-night stay in a luxurious suite at Le Méridien Melbourne, offering you an exceptional birds-eye view over the bustling streets of Melbourne. A daily buffet breakfast for two adults and VIP Valet parking is included. All you have to do is enter the giveaway via Instagram. The winner will be announced on Tuesday, 29 April.

Browse even more hotel deals and save on stays with up to 50% off hotel promo codes, available from 3 pm AEST on 15 April until 11:59 pm AEST on 15 April, on a first-come, first-served basis, while stocks last.  

 Other Easter Mega Sale highlights include:

  • Enjoy up to $15 off top attractions, or pick up Buy 1 Get 1 on Universal Studios Singapore and Universal Studios Japan.
  • Stay connected with 50% off eSIMs.

Don’t miss out! Book your dream vacation with the best promotions and save big this holiday. Visit Trip.com’s Easter Sale for full T&Cs and start planning your next getaway, or download the Trip.com app by scanning the QR code on the website.

About Trip.com

Trip.com is an international one-stop travel service provider, available in 24 languages across 39 countries and regions in 35 local currencies. Trip.com has an extensive hotel and flight network consisting of more than 1.7 million hotels and flights from over 600 airlines covering 3,400 airports in 220 countries and regions around the globe. Trip.com’s world-class 24/7 multilingual customer service, as well as additional centres in Edinburgh, Tokyo and Seoul, help to ‘create the best travel experience’ for its millions of customers worldwide. To book your next trip, visit trip.com.

 

Advancing Circular Economy: Sorbent Tissues Drive Sustainable Solutions in Australia

JAKARTA, Indonesia, April 7, 2025 /PRNewswire/ — The Australian government recently introduced the Circular Economy Framework, a strategic initiative designed to boost sustainability and economic growth. The framework aims to double the country’s circularity by 2025, potentially adding $26 billion to the GDP by 2035 and reducing greenhouse gas emissions by 14%.

With sustainability driving business growth, 67% of Australian companies report financial benefits from their green strategies, according to SAP. Sustainable products may have higher upfront costs, the long-term advantages, such as improved efficiency, stronger brand reputation, and increased customer loyalty, outweigh the initial investment. As a result, more businesses are prioritizing sustainability, with 49% planning to increase spending over the next three years, up from 38% last year.

Aligning with this momentum, APP Group, through its strategic supply partnership with Sorbent, integrates sustainability into its operations in Australia, embedding eco-friendly practices to support the country’s circular economy.”

“At Sorbent we understand that toilet paper is a basic necessity in Australia, and we are committed to ensuring this essential product is produced sustainably,” stated Steve Nicholson, ANZ Director for Sorbent Paper Company. “We aim to support the Australian government’s new Circular Economy Framework and assist businesses in adopting sustainable practices as well.”

Sustainability plays a key role in how Sorbent manages their product manufacturing. Sorbent uses fibers from responsibly managed plantations, where fast-growing trees enable them to use less land while maintaining high product quality. Sorbent is PEFC-certified (Programme for the Endorsement of Forest Certification), ensuring that 100% of its raw materials are either PEFC CoC certified or sourced responsibly in accordance with PEFC guidelines.

Sorbent actively support Australia’s sustainability efforts by prioritizing responsible sourcing, efficient manufacturing, and eco-friendly innovations. Their commitment drives industry progress while meeting the increasing demand for sustainable products.

About APP Group

APP is a leading pulp, paper, and forestry company based in Indonesia, supplying high-quality tissue, packaging, and paper to over 150 countries. With operations in Indonesia and China, we prioritize sustainability, ethical practices, and the well-being of our employees, society, and the environment. Our Sustainability Roadmap Vision 2030, aligned with ESG principles, guides our efforts in environmental protection, community support, biodiversity preservation, and carbon neutrality.

 

/R E P E A T — MEDIA ADVISORY – Canada’s No. 1 Hospital to announce strategy to attract world’s most promising scientists to drive health innovation and economic growth/

TORONTO, April 6, 2025 /PRNewswire/ —

WHAT: Canada’s No. 1 Hospital, University Health Network (UHN) is unveiling an ambitious strategy aimed at attracting the brightest minds in medical research to Canada, whose work will help fuel economic development, Canadian-based manufacturing and high-quality jobs.

WHEN: Monday, April 7, 2025, at 11:30 a.m. — Media, please arrive 15 minutes prior.

WHERE: UHN’s Toronto General Hospital, 200 Elizabeth Street, Toronto, ON  

WHO: 

  • Hon. Doug Ford, Premier of Ontario 
  • Hon. Sylvia Jones, Deputy Premier of Ontario and Minister of Health 
  • Dr. Kevin Smith, President & CEO, UHN 
  • Dr. Brad Wouters, Executive Vice President, Science & Research, UHN 
  • Mr. Cornell Wright, Deputy Chair, UHN Board of Trustees 

Remarks will start promptly at 11:45 a.m. 

For those outside the city of Toronto, event will be live streamed starting 11:45 am 

More information at www.UHNCanadaleads.ca  

RSVP: Please send confirmation of journalists attending to ana.fernandes@uhn.ca